Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line

Molecular Cancer Research

Volumn 8, Issue 4, 2010, Pages 604-614

  Sheriff, Sulaiman ^a   Ali, Marwan ^a   Yahya, Ayesha ^a   Haider, Khawaja H ^a   Balasubramaniam, Ambikaipakan ^a   Amlal, Hassane ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; CALCIUM ION; CYCLIC AMP; FORSKOLIN; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NUCLEAR FACTOR Y; PEPTIDE YY; PERTUSSIS TOXIN;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CALCIUM MOBILIZATION; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCREENING TEST; TUMOR GROWTH;

BINDING SITES; BINDING, COMPETITIVE; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FORSKOLIN; HUMANS; NAPHTHALENES; NEOPLASM INVASIVENESS; NEUROPEPTIDE Y; PHOSPHORYLATION; PYRIMIDINES; RECEPTORS, NEUROPEPTIDE Y;

EID: 77951152245     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0301     Document Type: Article

References (50)

1. Balasubramaniam A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 1997;18:445-457 (Pubitemid 27224378)
2. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998;83:187-195 (Pubitemid 28354463)
3. Groneberg DA, Folkerts G, Peiser C, Chung KF, Fischer A. Neuropeptide Y (NPY). Pulm Pharmacol Ther 2004;17:173-180
4. Chronwall BM, Zukowska Z. Neuropeptide Y, ubiquitous and elusive. Peptides 2004;25:359-363
5. Clark JT, Kalra PS, Kalra SP. Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 1985;117: 2435-2442
6. Ammar DA, Eadie DM, Wong DJ, et al. Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics 1996;38:392-398
7. Herzog H, Darby K, Ball H, Hort Y, Beck-Sickinger A, Shine J. Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. Genomics 1997;41:315-319 (Pubitemid 27194781)
8. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlestedt C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 1992;267:10935-10938
9. Wahlestedt C, Grundemar L, Håkanson R, et al. Neuropeptide Y receptor subtypes, Y1 and Y2. Ann N Y Acad Sci 1990;611:7-26.
10. Kalra PS, Dube MG, Xu B, Farmerie WG, Kalra SP. Neuropeptide Y (NPY) Y1 receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: evidence for a hypothalamic site for concurrent development of leptin resistance. J Neuroendocrinol 1998;10:43-49 (Pubitemid 28055036)
11. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940-944
12. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 1994;50:259-265 (Pubitemid 24110242)
13. Sheriff S, Dayal R, Kasckow J, et al. NPY upregulates genes containing cyclic AMP response element in human neuroblastoma cell lines bearing Y1 and Y2 receptors: involvement of CREB. Regul Pept 1998;75-76:309-318 (Pubitemid 28477542)
14. Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005;65:1719-1728 (Pubitemid 40478597)
15. Reubi JC, Gugger M, Waser B, Schaer JC. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-4641
16. Grisé KR, Rongione AJ, Laird EC, McFadden DW. Peptide YY inhibits growth of human breast cancer in vitro and in vivo. J Surg Res 1999;82:151-155 (Pubitemid 29394117)
17. Amlal H, Faroqui S, Balasubramaniam A, Sheriff S. Estrogen upregulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res 2006;66:3706-3714
18. Parker SL, Balasubramaniam A. Neuropeptide Y Y2 receptor in health and disease. Br J Pharmacol 2008;153:420-431
19. Körner M, Reubi JC. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J Neuropathol Exp Neurol 2008;67:741-749
20. Körner M, Waser B, Reubi JC. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin Cancer Res 2004;10:8426-8433 (Pubitemid 40053406)
21. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996;382:168-171
22. Pellieux C, Sauthier T, Domenighetti A, et al. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A 2000;97:1595-1600
23. Yahya A, Xiao C, Chance WT, Sheriff S. Up-regulation of neuropeptide Y Y4 receptor mRNA expression in the brainstem of refed rats following 48 h of food deprivation: effect of leptin. Peptides 2006;27:2731-2737
24. Chance WT, Dayal R, Friend LA, Thomas I, Sheriff S. Continuous intravenous infusion of ghrelin does not stimulate feeding in tumor-bearing rats. Nutr Cancer 2008;60:75-90.
25. Parker EM, Babij CK, Balasubramaniam A, et al. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur J Pharmacol 1998;349:97-105.
26. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R. Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol 2003;139:1360-1368
27. Zinser GM, McEleney K, Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol 2003;200:67-80.
28. Cabrele C, Langer M, Bader R, et al. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem 2000;275:36043-36048
29. Criscione L, Rigollier P, Batzl-Hartmann C, et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 1998;102:2136-2145
30. Jiang S, Haider HKH, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006;99:776-784
31. Thangasamy A, Rogge J, Ammanamanchi S. Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells. J Biol Chem 2008;283:5335-5343
32. Della Zuana O, Sadlo M, Germain M, et al. Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int J Obes Relat Metab Disord 2001;25:84-94.
33. Onuoha GN, Nugent AM, Hunter SJ, et al. Neuropeptide variability in man. Eur J Clin Invest 2000;30:570-577
34. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007;58 Suppl 1:13-35.
35. Tong J, Utzschneider KM, Carr DB, et al. Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects. Diabetologia 2007;50:439-442
36. Bischoff A, Püttmann K, Kötting A, Moser C, Buschauer A, Michel MC. Limited signal transduction repertoire of human Y(5) neuropeptide Y receptors expressed in HEC-1B cells. Peptides 2001;22:387-394
37. Pons J, Kitlinska J, Jacques D, et al. Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Can J Physiol Pharmacol 2008;86:438-448
38. Lowe WL, Jr., Fu R, Banko M. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3′,5′- monophosphate in MCF-7 breast cancer cells. Endocrinology 1997;138:2219-2226
39. Starzec AB, Spanakis E, Nehme A, et al. Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis. J Cell Physiol 1994;161:31-38
40. Drees M, Zimmermann R, Eisenbrand G. 3′, 5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 1993;53:3058-3061
41. Tortora G, di Isernia G, Sandomenico C, et al. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 1997;57:5107-5111
42. Burns DL. Subunit structure and enzymic activity of pertussis toxin. Microbiol Sci 1988;5:285-287
43. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′, 5′-monophosphate. Science 1993;262:1065-1069
44. Sevetson BR, Kong X, Lawrence JC, Jr. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A 1993;90:10305-10309
45. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999;11:211-218
46. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268-275
47. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632
48. Ruscica M, Dozio E, Motta M, Magni P. Relevance of the neuropeptide Y system in the biology of cancer progression. Curr Top Med Chem 2007;7:1682-1691 (Pubitemid 350131005)
49. Morin SM, Gehlert DR. Distribution of NPY Y5-like immunoreactivity in the rat brain. J Mol Neurosci 2006;29:109-114
50. Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 2003;81:89-94.